Bilgin AÖ. Can Serotonin 7 Receptors Be a Treatment Target for Noncentral Diseases?
Eurasian J Med 2023;
55:S49-S54. [PMID:
39128036 DOI:
10.5152/eurasianjmed.2023.23303]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/13/2024] Open
Abstract
The neurotransmitter serotonin (5-HT) is involved in several key processes in the central nervous system. But the great majority of serotonin is produced by intestinal enterochromafn cells of the gastrointestinal (GI) tract and circulating blood platelets, which work independently of the central nervous system. The mediating pathway through which serotonin transmits its efects is the 5-HT receptor (5-HTR) superfamily, which consists of at least 14 members with extensive characterizations. Having been discovered as the final member of the 5-HTR family, 5-HT7 receptors have specific roles in the neurological, GI, circulatory, and immune systems. Due to their extensive distribution, these receptors' stimulation and repression are of importance during the therapy process, even if their exact mechanism of action in disease has not been fully understood. This review establishes the functions of 5-HT7Rs in systems and discusses how these receptors may be used therapeutically to treat peripheral diseases.
Collapse